JPH11507804A - 癌自己関連抗原特異的ヒト細胞障害性t細胞の産生とその使用 - Google Patents
癌自己関連抗原特異的ヒト細胞障害性t細胞の産生とその使用Info
- Publication number
- JPH11507804A JPH11507804A JP8525765A JP52576596A JPH11507804A JP H11507804 A JPH11507804 A JP H11507804A JP 8525765 A JP8525765 A JP 8525765A JP 52576596 A JP52576596 A JP 52576596A JP H11507804 A JPH11507804 A JP H11507804A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- host
- cell
- cea
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 94
- 239000000427 antigen Substances 0.000 title claims abstract description 88
- 108091007433 antigens Proteins 0.000 title claims abstract description 85
- 102000036639 antigens Human genes 0.000 title claims abstract description 85
- 201000011510 cancer Diseases 0.000 title claims abstract description 80
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 73
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 54
- 239000013598 vector Substances 0.000 claims abstract description 38
- 241000700605 Viruses Species 0.000 claims abstract description 37
- 230000001939 inductive effect Effects 0.000 claims abstract description 25
- 239000002671 adjuvant Substances 0.000 claims abstract description 22
- 239000012634 fragment Substances 0.000 claims abstract description 17
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 13
- 238000003780 insertion Methods 0.000 claims abstract description 12
- 230000037431 insertion Effects 0.000 claims abstract description 12
- 239000002502 liposome Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 94
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 73
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 17
- 208000007089 vaccinia Diseases 0.000 claims description 16
- 244000144977 poultry Species 0.000 claims description 12
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims description 5
- 241000700664 Capripoxvirus Species 0.000 claims description 4
- 241000700629 Orthopoxvirus Species 0.000 claims description 4
- 241000287219 Serinus canaria Species 0.000 claims description 4
- 238000013507 mapping Methods 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 241000272201 Columbiformes Species 0.000 claims description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 208000000666 Fowlpox Diseases 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 24
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 24
- 230000003053 immunization Effects 0.000 description 24
- 238000002649 immunization Methods 0.000 description 23
- 239000002609 medium Substances 0.000 description 23
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 18
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 17
- WEYNBWVKOYCCQT-UHFFFAOYSA-N 1-(3-chloro-4-methylphenyl)-3-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)thio]ethyl}urea Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)NC1=CC=C(C)C(Cl)=C1 WEYNBWVKOYCCQT-UHFFFAOYSA-N 0.000 description 15
- 101710137115 Adenylyl cyclase-associated protein 1 Proteins 0.000 description 15
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 15
- 230000005867 T cell response Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- 101150045267 CEA gene Proteins 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 108020004440 Thymidine kinase Proteins 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 102000006601 Thymidine Kinase Human genes 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 241000701447 unidentified baculovirus Species 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 3
- 241000282994 Cervidae Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 101150003725 TK gene Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002494 anti-cea effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000003255 drug test Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 241000700663 Avipoxvirus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241000609499 Palicourea Species 0.000 description 2
- 241000700638 Raccoonpox virus Species 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 108010073443 Ribi adjuvant Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- LFRXCNXVZHVRSE-JEZACWOJSA-N [(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r)-3-hydroxy-2-tetradecyloctadecanoyl]oxymethyl]oxan-2-yl]oxyoxan-2-yl]methyl (2r,3r)-3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)[C@H](CCCCCCCCCCCCCC)[C@H](O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)[C@H](CCCCCCCCCCCCCC)[C@H](O)CCCCCCCCCCCCCCC)O1 LFRXCNXVZHVRSE-JEZACWOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000011467 adoptive cell therapy Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004520 cell wall skeleton Anatomy 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101001034843 Mus musculus Interferon-induced transmembrane protein 1 Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001274197 Scatophagus argus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241001536558 Yaba monkey tumor virus Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000021310 complex sugar Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- LIAWOTKNAVAKCX-UHFFFAOYSA-N hydrazine;dihydrochloride Chemical compound Cl.Cl.NN LIAWOTKNAVAKCX-UHFFFAOYSA-N 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108700022109 ropocamptide Proteins 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.a)細胞障害性T細胞の生産を刺激するために宿主に第1のポックスウイル スベクターの充分量を導入すること;そのポックスウイルスベクターは宿主内で 発現可能なプロモーターに操作可能に連結した癌自己関連抗原(Carcinoma self -associated antigen)又はそのエピトープをコードする DNA 断面を含有する少 なくとも1つの挿入部位を持つものであり、 b)少なくとも1回の一定間隔後宿主を追加抗原と接触させること、 を含んでなる癌自己関連抗原に特異的なヒト細胞障害性T細胞の生産方法。 2.宿主内で発現可能なプロモーターに操作可能に連結した癌自己関連抗原又は そのエピトープをコードする DNA 断片を含有する少なくとも1つの挿入部位を 持つ宿主に、第2のポックスウイルスベクターを導入することにより宿主を追加 抗原と接触させる請求の範囲第1項の方法。 3.癌自己関連抗原が癌胚抗原(Carcinoembryonic antigen)である請求の範囲 第1項の方法。 4.エピトープが配列表の配列番号1,2,3,4,5,6,7,8,9および 10として示されたペプチドの群から選ばれたペプチドを含むものである請求の 範囲第1項の方法。 5.エピトープが配列表の配列番号1として示されたペプチドを含むものである 請求の範囲第1項の方法。 6.ポックスウイルスがシューポックス(suipox)、アビポックス(avipox)、 カプリポックス(capripox)およびオルトポックス(orthopox)ウイルスからな るポックスウイルスの群から選ばれたものである請求の範囲第1項の方法。 7.オルトポックスがワクニシア(vaccinia)である請求の範囲第6項の方法。 8.アビポックスが家禽ポックス(fowlpox)、カナリヤポックス(canary pox )およびハトポックス(pigeon pox)である請求の範囲第5項の方法。 9.シューポックスがスワインポックス(swinepox)である請求の範囲第5項の 方法。 10.第1のポックスウイルスベクターがワクニシアであり、第2のポックスウイ ルスベクターがシューポックス、アビポックス、カプリポックスおよびオルトポ ックスウイルスからなるポックスウイルスの群から選ばれたものである請求の範 囲第2項の方法。 11.a)細胞障害性T細胞の生産を刺激するために宿主に第1のポックスウイル スベクターの充分量を導入すること;そのポックスウイルスベクターは宿主内で 発現可能なプロモーターに操作可能に連結した癌自己関連抗原又はそのエピトー プをコードする DNA 断面を含有する少なくとも1つの挿入部位を持つものであ り、 b)少なくとも1回の一定間隔後宿主を追加抗原と接触させること、および c)宿主から癌関連抗原に特異的な細胞障害性T細胞を単離すること、 を含んでなる癌自己関連抗原に特異的なヒト細胞障害性T細胞の単離方法。 12.さらに、 d)工程c)で単離された細胞を癌自己関連抗原又はそのエピトープとIL −2を交互に接触させることによりT細胞の数を増すことを含んでなる請求の範 囲第11項の方法。 13.a)細胞障害性T細胞の生産を刺激するために宿主に第1のポックスウイル スベクターの充分量を導入すること;そのポックスウイルスベクターは宿主内で 発現可能なプロモーターに操作可能に連結した癌自己関連抗原又はそのエピトー プをコードする DNA 断面を含有する少なくとも1つの挿入部位を持つものであ り、 b)少なくとも1回の一定間隔後宿主を追加抗原と接触させること、 c)宿主から癌自己関連抗原に特異的な細胞障害性T細胞を単離すること、 d)工程c)で得られたT細胞を予備選択されたエピトープと接触させ、該 エピトープを認識するT細胞を選択すること、 を含んでなる癌自己関連抗原のエピトープのマッピング方法。 14.癌自己関連抗原の細胞障害性T細胞誘発性エピトープを宿主に導入すること を含んでなる癌自己関連抗原に特異的なヒト細胞障害性T細胞の生産方法。 15.追加のT細胞誘発性エピトープを少なくとも1回の一定間隔後宿主に導入す る請求の範囲第14項の方法。 16.T細胞誘発性エピトープがアジュバントを用いて製剤化されているか、また はリポソーム製剤中に存在する請求の範囲第15項の方法。 17.アジュバントが RIBI デトックス(Detox),QS21 および不完全フロイント アジュバントからなる群から選ばれたものである請求の範囲第16項の方法。 18.癌自己関連抗原が CEA である請求の範囲第14項の方法。 19.T細胞誘発性エピトープが配列表の配列番号1,2,3,4,5,6,7, 8,9および10として示されたペプチドからなる群から選ばれたものである請 求の範囲第14項の方法。 20.T細胞誘発性エピトープが配列表の配列番号1で示されるペプチドである請 求の範囲第19項の方法。 21.癌自己関連抗原のT細胞誘発性エピトープを宿主に導入し、宿主から癌関連 抗原に特異的な細胞障害性T細胞を単離することを含んでなる癌自己関連抗原に 特異的なヒト細胞障害性T細胞の単離方法。 22.さらに、 単離された細胞障害性T細胞に癌自己関連抗原のたはそのエピトープおよび IL−2を交互に接触させることによりT細胞の数を増すことを含んでなる請求 の範囲第21項の方法。 23.T細胞誘発性エピトープがアジュバントを用いて製剤化されているか、また はリポソーム製剤中に存在する請求の範囲第21項の方法。 24.アジュバントが RIBI デトックス,QS21 および不完全フロイントアジュバ ントからなる群から選ばれたものである請求の範囲第23項の方法。 25.癌自己関連抗原が CEA である請求の範囲第21項の方法。 26.T細胞誘発性エピトープが配列表の配列番号1,2,3,4,5,6,7, 8,9および10として示されたペプチドからなる群から選ばれたものである請 求の範囲第25項の方法。 27.T細胞誘発性エピトープが配列表の配列番号1として示されたペプチドであ る請求の範囲第26項の方法。 28.抗原に特異的な細胞障害性T細胞を宿主に導入し、少なくとも1回の一定間 隔後癌自己関連抗原のT細胞誘発性エピトープを宿主に導入することを含んでな る癌自己関連抗原を発現している腫瘍を持つ宿主を治療する方法。 29.T細胞誘発性エピトープがアジュバントを用いて製剤化されているか、また はリポソーム製剤中に存在する請求の範囲第28項の方法。 30.アジュバントが RIBI デトックス,QS21 および不完全フロイントアジュバ ントからなる群から選ばれたものである請求の範囲第29項の方法。 31.癌自己関連抗原が CEA である請求の範囲第28項の方法。 32.T細胞誘発性エピトープが配列表の配列番号1,2,3,4,5,6,7, 8,9および10に示されたペプチドからなる群から選ばれたものである請求の 範囲第31項の方法。 33.T細胞誘発性エピトープが配列表の配列番号1として示されたペプチドであ る請求の範囲第32項の方法。 34.配列表の配列番号1,2,3,4,5,6,7,8,9および10として示 されたペプチドからなる群から選ばれたペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/396,385 US6001349A (en) | 1995-02-22 | 1995-02-22 | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
US08/396,385 | 1995-02-22 | ||
PCT/US1996/002156 WO1996026271A1 (en) | 1995-02-22 | 1996-02-13 | Generation of human cytotoxic t-cells specific for carcinoma self-associated antigens and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507804A true JPH11507804A (ja) | 1999-07-13 |
JP4059920B2 JP4059920B2 (ja) | 2008-03-12 |
Family
ID=23566990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52576596A Expired - Lifetime JP4059920B2 (ja) | 1995-02-22 | 1996-02-13 | 癌自己関連抗原特異的ヒト細胞障害性t細胞の産生とその使用 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6001349A (ja) |
EP (1) | EP0811062B1 (ja) |
JP (1) | JP4059920B2 (ja) |
AU (1) | AU711899B2 (ja) |
CA (1) | CA2213451C (ja) |
DE (1) | DE69637969D1 (ja) |
DK (1) | DK0811062T3 (ja) |
ES (1) | ES2329427T3 (ja) |
PT (1) | PT811062E (ja) |
WO (1) | WO1996026271A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005529170A (ja) * | 2002-06-11 | 2005-09-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | T細胞エピトープをマッピングおよび除去する方法 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US6946133B1 (en) * | 1996-03-20 | 2005-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Prostate specific antigen oligo-epitope peptide |
US20010036928A1 (en) * | 1996-04-22 | 2001-11-01 | Chamberlain Ronald S. | Heterologous boosting immunizations |
EP2112225A1 (en) * | 1996-07-25 | 2009-10-28 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Recombinant pox virus for immunization against tumor-associated antigens |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
JP2001515052A (ja) * | 1997-08-13 | 2001-09-18 | ザ ユーエイビー リサーチ ファンデーション | 遺伝子ベクターの局所施用によるワクチン接種 |
WO1999019478A1 (en) * | 1997-10-10 | 1999-04-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
EP1447414B1 (en) * | 1997-10-10 | 2007-06-06 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Antagonist peptides of carcinoembryonic antigen (CEA) |
US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US7060670B1 (en) * | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
DK1092779T3 (da) * | 1999-10-11 | 2010-02-15 | Pasteur Institut | Lentiviirusvektorer til fremstilling af immunterapeutiske præparater |
ATE391726T1 (de) | 1999-10-22 | 2008-04-15 | Sanofi Pasteur Ltd | Modifiziertes gp100 und dessen verwendung |
WO2001085932A2 (en) | 2000-05-10 | 2001-11-15 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
CA2416893A1 (en) * | 2000-07-31 | 2002-02-07 | Aventis Pasteur Limited | Modified cea and uses thereof |
CA2421448A1 (en) * | 2000-09-01 | 2002-03-14 | Epimmune Inc. | Hla binding peptides and their uses |
EP1370668B1 (en) * | 2001-03-08 | 2006-02-22 | Akzo Nobel N.V. | Leporipox-based vector vaccines |
GB0118532D0 (en) | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
US7247297B2 (en) * | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
WO2003085087A2 (en) | 2002-04-09 | 2003-10-16 | Aventis Pasteur, Limited | Modified cea nucleic acid and expression vectors |
CN1596126A (zh) | 2001-11-30 | 2005-03-16 | 埃西斯创新有限公司 | 疫苗 |
AU2003225866A1 (en) * | 2002-03-22 | 2003-10-13 | Aventis Pasteur, Inc. | Peptide epitopes recognized by antigen specific cd8+ t lymphocytes |
EP1556082A1 (en) * | 2002-10-22 | 2005-07-27 | Aventis Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
JP4668919B2 (ja) * | 2003-10-08 | 2011-04-13 | サノフィ パストゥール インコーポレイテッド | 修飾cea/b7ベクター |
AU2004299457B2 (en) * | 2003-12-12 | 2011-03-24 | Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1 |
US20090060947A1 (en) * | 2006-05-19 | 2009-03-05 | Sanofi Pasteur, Inc. | Immunological compositions |
EP2125868B1 (en) | 2007-02-28 | 2015-06-10 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
WO2010127115A1 (en) | 2009-04-30 | 2010-11-04 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
EP3153861A3 (en) | 2010-08-06 | 2017-06-07 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Biomarkers for predicting response to a cancer vaccine |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
US10221249B2 (en) | 2015-09-10 | 2019-03-05 | Affigen, Llc | Method of making patient specific anti-idiotype antibodies |
US20190183870A1 (en) | 2016-01-05 | 2019-06-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Combination of histone deacetylase inhibitor and immunotherapy |
WO2017136342A1 (en) | 2016-02-02 | 2017-08-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells |
CN116458475A (zh) | 2016-06-03 | 2023-07-21 | 瑞泽恩制药公司 | 表达外源末端脱氧核苷酸转移酶的非人动物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
ATE96168T1 (de) * | 1986-08-13 | 1993-11-15 | Miles Inc | Karzinoembryonisches antigen kodierende cdns. |
JPH02107189A (ja) * | 1988-05-25 | 1990-04-19 | City Of Hope | 癌胎児抗原フラグメント |
ES2206446T3 (es) * | 1991-05-06 | 2004-05-16 | The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services | Virus recombinante que expresa un antigeno carcinoembrionico y metodos de uso del mismo. |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5764734A (en) * | 1994-12-21 | 1998-06-09 | Motorola, Inc. | Method and system for controlling access to a channel |
-
1995
- 1995-02-22 US US08/396,385 patent/US6001349A/en not_active Expired - Lifetime
-
1996
- 1996-02-13 DK DK96907061T patent/DK0811062T3/da active
- 1996-02-13 PT PT96907061T patent/PT811062E/pt unknown
- 1996-02-13 CA CA2213451A patent/CA2213451C/en not_active Expired - Lifetime
- 1996-02-13 AU AU50240/96A patent/AU711899B2/en not_active Ceased
- 1996-02-13 ES ES96907061T patent/ES2329427T3/es not_active Expired - Lifetime
- 1996-02-13 JP JP52576596A patent/JP4059920B2/ja not_active Expired - Lifetime
- 1996-02-13 DE DE69637969T patent/DE69637969D1/de not_active Expired - Lifetime
- 1996-02-13 EP EP96907061A patent/EP0811062B1/en not_active Expired - Lifetime
- 1996-02-13 WO PCT/US1996/002156 patent/WO1996026271A1/en active Application Filing
-
1999
- 1999-04-06 US US09/287,221 patent/US6319496B1/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005529170A (ja) * | 2002-06-11 | 2005-09-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | T細胞エピトープをマッピングおよび除去する方法 |
Also Published As
Publication number | Publication date |
---|---|
US6319496B1 (en) | 2001-11-20 |
US6001349A (en) | 1999-12-14 |
EP0811062A1 (en) | 1997-12-10 |
AU711899B2 (en) | 1999-10-21 |
PT811062E (pt) | 2009-09-28 |
DK0811062T3 (da) | 2009-10-26 |
CA2213451A1 (en) | 1996-08-29 |
DE69637969D1 (de) | 2009-08-27 |
JP4059920B2 (ja) | 2008-03-12 |
AU5024096A (en) | 1996-09-11 |
EP0811062B1 (en) | 2009-07-15 |
ES2329427T3 (es) | 2009-11-25 |
WO1996026271A1 (en) | 1996-08-29 |
CA2213451C (en) | 2013-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4059920B2 (ja) | 癌自己関連抗原特異的ヒト細胞障害性t細胞の産生とその使用 | |
JP4776852B2 (ja) | 癌抗原nyeso−1由来の新規mhcクラスii拘束t細胞エピトープ | |
AU712714B2 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system | |
JP4633867B2 (ja) | 前立腺特異的抗原(psa)に対する免疫応答の発生 | |
CA2245702A1 (en) | Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same | |
JP2002531133A (ja) | 複数の共刺激分子を発現する組換えベクターおよびその利用 | |
US20070048860A1 (en) | Carcinoembryonic antigen (CEA) peptides | |
JP2012144563A (ja) | 化学免疫療法の方法 | |
JP2004507231A (ja) | 免疫応答を向上させるための、gm−csfを発現する組換え非−複製性ウィルスおよびその使用 | |
JP2008142086A (ja) | 改良された予防接種戦略に関する材料及び方法 | |
US20040009185A1 (en) | Enhancing the immune response to an antigen by presensitzing with an inducing agent prior to immunizing with the agent and the antigen | |
US8021666B2 (en) | Method and compositions for stimulation of an immune response to CD20 using a xenogeneic CD20 antigen | |
JP4533630B2 (ja) | ヒト5t4腫瘍関連抗原由来のmhcクラスiペプチドエピトープ | |
JP2007523610A (ja) | 癌胎児抗原をコードする合成遺伝子およびその使用 | |
US20020164318A1 (en) | Cell lines and vectors for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen | |
US20040131598A1 (en) | Cancer therapy | |
AU2011201813A1 (en) | Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer | |
Ngo-Giang-Huong et al. | Mutations in residue 61 of H-Ras p21 protein influence MHC class II presentation | |
HODGE et al. | CARCEVOEMBRYONIC ANTIGEN (CEA) AS A MODEL FOR IMMUNOTHERAPY USING RECOMBINANT VACCINES | |
Stanners | CARCEVOEMBRYONIC ANTIGEN (CEA) AS A MODEL FOR IMMUNOTHERAPY USING RECOMBINANT VACCINES | |
Hunter | Tafuro et al.(43) Pub. Date: Jul. 8, 2004 | |
AU2016202443A1 (en) | Immunogenic control of tumours and tumour cells | |
AU2013270496A1 (en) | Immunogenic control of tumours and tumour cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051201 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060725 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20061218 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070528 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070725 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070913 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070925 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071219 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101228 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111228 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121228 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131228 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |